에 대한 최신 뉴스 AstraZeneca (NASDAQ:AZN) 주식

AstraZeneca

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its sales.

Long Ideas

Hedge Funds

Trading Ideas

BABA

ALIBABA GROUP HOLDING LTD by Alibaba Group Holding Limited

BABAF

GOOGL

ORCL

iShares Trust Barclays 20+ Year Treasury Bond Fund

억만장자 투자자 조지 소로스는 4분기에 대담한 포트폴리오 조정을 단행하여 방어적 베팅을 완화하고 성장 쪽으로 방향을 전환했다. 소로스 펀드 매니지먼트의 최신 13F 제출서는 알파벳(NASDAQ:GOOGL)과 소형주들에 대한 새로운 베팅을 보여주었으며, SPDR S&amp;P 500 ETF(NYSE:SPY) 풋 포지션을 대폭 줄였다.

조지 소로스가 알파벳과 소형주들에 새로운 베팅: SPY 풋 옵션과 알리바바는 어떻게?

Equities

News

Markets

Movers

General

ACHL

아킬레스 테라퓨틱스(NASDAQ:ACHL)의 주식은 회사가 아스트라제네카(NASDAQ:AZN)와 1,200만 달러 규모의 계약을 발표하고, 일자리 감축 계획을 밝힌 후 화요일 16% 이상 급등했다. 이번 계약은 아킬레스의 TRACERx 비소세포폐암(NSCLC) 연구로부터 데이터와 종양 샘플에 대한 상업적 라이선스 이전을 아스트라제네카에 허용하는 내용을 포함하고 있다.

아킬레스 테라퓨틱스: $1,200만 아스트라제네카와의 계약 발표, 직원 감축 발표 후 주가 급등

Large Cap

AKAM

FSLR

MELI

MRNA

PINS

지난주 카멀라 해리스가 2024년 미국 대선에서 패배하면서 다음 10개의 대형 주식이 가장 저조한 성과를 보였다. 

카멀라 해리스 대선 패배 주간(11월 4~8일) 대폭 하락한 대형주 10종목

AstraZeneca PLC - American Depositary Shares

AstraZeneca PLC

Precidian ETFs Trust AstraZeneca PLC ADRhedged

AZN Capital Corp

<a href="https://www.dailymail.co.uk/galleries/article-14422269/New-coronavirus-pandemic-potential-discovered-China.html">https://www.dailymail.co.uk/galleries/article-14422269/New-coronavirus-pandemic-potential-discovered-China.html</a>
&nbsp;

Biotech

Macro Economic Events

Global

Economics

BNTX

NVAX

'New Coronavirus With Pandemic Potential Discovered In China' - DailyMail

AMGN

DRIO

Hims & Hers Health, Inc. Class A Common Stock

HIMS

LFVN

RHHBY

TERN

VANI

VKTX

FDA Says Novo Nordisk's Ozempic Injection .68 mg/1 ml, Injection 1.34 mg/1 ml, Injection 2.68 Mg/1 ml Available As Of Feb 21; Novo Nordisk's Wegovy, Injection, 1.7 mg/.75 ml , Wegovy, Injection, 2.4 mg/.75 ml Now Available; FDA Says Semaglutide Injection Shortage Is Resolved As Of Feb 21

FibroGen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGEN#NASDAQ">FGEN</a>) stock is trading higher on Thursday. The company&nbsp;announced the sale of its China subsidiary to AstraZeneca Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) for <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43842973/fibrogen-announces-the-sale-of-fibrogen-china-to-astrazeneca-for-approximately-160-million" rel="noreferrer noopener">approximately $160 million</a>.
&#8220;Today, we announced the sale of FibroGen China to AstraZeneca, our long-time strategic partner for roxadustat in China, bolstering our company on several fronts. It strengthens our financial position, meaningfully extending our cash runway into 2027, and enables us to continue progressing the clinical development program for FG-3246, our first-in-class, CD46 targeting antibody-drug conjugate, and FG-3180, our companion PET imaging agent, in mCRPC,&#8221; said Thane Wettig, Chief Executive Officer of FibroGen.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/43065029/astrazeneca-aims-to-restore-trust-with-new-leadership-in-china-amid-scandal-and-sales-decline" rel="noreferrer noopener">AstraZeneca Aims to Restore Trust With New Leadership in China Amid Scandal and Sales Decline</a>
FibroGen will receive an enterprise value of $85 million plus FibroGen net cash in China at closing, estimated to be approximately $75 million, totaling roughly $160 million. The transaction is expected to close by mid-2025.
AstraZeneca will obtain all rights to roxadustat for anemia in chronic kidney disease in China. A regulatory decision for chemotherapy-induced anemia is pending.
FibroGen maintains its rights to roxadustat in the U.S. and in all markets not licensed to Astellas. The company continues to evaluate a development plan for roxadustat in anemia associated with lower-risk myelodysplastic syndrome.
The company is planning for an FDA meeting in the second quarter of 2025 to determine the potential next steps for the development program for roxadustat in the U.S.
In relation to the illegal drug importation allegations, in January 2025, AstraZeneca received a Notice of Transfer to the Prosecutor and an Appraisal Opinion from the Shenzhen City Customs Office regarding suspected unpaid importation taxes amounting to $0.9 million, referred to in the Appraisal Opinion relate to cancer drugs, <a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43527514/astrazeneca-q4-earnings-revenue-and-eps-beat-on-higher-cancer-and-respiratory-drug-sales-faces-4-5-million-potential-fine-in-china" rel="noreferrer noopener">Imfinzi and Imjudo</a>.
A fine of one and five times unpaid importation taxes may also be levied if AstraZeneca is found liable (amounting to around $0.9 million to $4.5 million). Reuters notes the update reassures analysts and investors that the business impact would be minor.
AstraZeneca&#8217;s China sales fell 1% on a reported basis to&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41907137/astrazeneca-lifts-2024-forecast-on-better-than-expected-q3-performance-says-it-takes-china-invest" rel="noreferrer noopener">$1.36 billion (-3% at CER)</a>.
Price Action: FGEN stock is up 21.6% at $0.68 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43852190/southern-company-q4-utility-growth-boosts-revenue-but-rising-costs-weigh-on-profit" target="_blank" rel="noreferrer noopener">Southern Company Q4: Utility Growth Boosts Revenue, But Rising Costs Weigh on Profit</a></li>
</ul>
Image by Robert Way via Shutterstock

Health Care

FGEN

Amid Mounting Pressure In China, AstraZeneca Buys FibroGen's Chinese Unit For $160 Million

<ul>
<li>&nbsp;Purchase price represents enterprise value of $85 million plus FibroGen net cash held in China at closing, currently estimated to be approximately $75 million</li>
<li>Upon close, FibroGen will repay its term loan to Morgan Stanley Tactical Value, further simplifying the Company's capital structure
<ul>
<li>Company's cash runway extended into 2027</li>
</ul>
</li>
<li>Company to continue to advance its oncology pipeline, with the initiation of the Phase 2 monotherapy trial of FG-3246 in metastatic castration-resistant prostate cancer (mCRPC) in 2Q 2025</li>
<li>Preliminary unaudited cash, cash equivalents, and accounts receivable of $121.1 million as of December 31, 2024</li>
</ul>

FibroGen Announced The Sale Of Its China Subsidiary To AstraZeneca For Approximately $160M

<a href="https://www.benzinga.com/topic/europe">European fund managers</a> are optimistic that rising economic growth will fuel a rally in the region's stocks.
This bullishness is already reflected in performance, per a Financial Times report. The Stoxx Europe 600 index has climbed nearly 10% in this year thus far, outpacing the S&amp;P 500's 4% rise and Japan's Topix, which has seen a slight decline.
For investors looking to ride this momentum, <a href="https://www.benzinga.com/etfs">here are three ETFs</a> offering strong exposure to European stocks:
SPDR Euro Stoxx 50 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FEZ#NYSE">FEZ</a>): The SPDR EURO STOXX 50 ETF has been gaining momentum, recently hitting a 52-week high and climbing 15.16% from its 52-week low of $47.11 per share.
<ul>
<li>What's inside? FEZ tracks the EURO STOXX 50 Index, which represents the performance of the largest companies in the Eurozone across 19 different sectors. With an annual expense ratio of 0.29%, it offers broad exposure to Europe's biggest players.</li>
<li>Why is it moving? Optimism over a <a href="https://www.benzinga.com/25/02/43791431/whats-driving-markets-tuesday">potential peace deal between Ukraine and Russia</a>, fueled by recent talks between U.S. and Russian officials, has lifted European equities. Strong earnings reports from major European firms have also contributed to the fund's rally.</li>
</ul>
Also Read: <a href="https://www.benzinga.com/news/global/25/02/43769730/ukraine-raises-alarm-over-us-russia-talks-on-war-without-kyivs-involvement">Ukraine Raises Alarm Over US-Russia Talks on War Without Kyiv&#8217;s Involvement</a>
Vanguard FTSE Europe ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VGK#NYSE">VGK</a>): This ETF provides a broader European exposure, with holdings in companies across sectors. Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOVO#NYSE">NOVO</a>), AstraZeneca (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) and Nestle are among the top names adorning the portfolio.
<ul>
<li>What's inside? VGK tracks the FTSE Developed Europe Index, covering a wide range of European equities beyond just the Eurozone, including the U.K. The fund's low expense ratio of 0.09% makes it a cost-effective way to gain diversified exposure.</li>
<li>Why is it moving? Sentiment around European stocks has improved. Investors are relieved that the EU, seen as a potential target of Trump's &#8220;America First&#8221; trade policies, has so far avoided new tariffs.</li>
</ul>
Xtrackers MSCI EAFE Hedged Equity ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DBEF#NYSE">DBEF</a>): Currency fluctuations can impact returns when investing in foreign stocks, which is where DBEF comes in. This fund offers exposure to European, Australasian, and Far Eastern stocks while hedging against currency risk.
<ul>
<li>What's inside? DBEF tracks the MSCI EAFE Index but incorporates a hedge against fluctuations in the U.S. dollar. This makes it an appealing option for U.S.-based investors looking to minimize currency-related volatility. The expense ratio is 0.36%.</li>
<li>Why is it moving? With the euro weakening against the dollar, European earnings might look more attractive to foreign investors. </li>
</ul>
<h2 class="wp-block-heading">Europe: The Best-Performing Equity Market</h2>
Bank of America's latest survey of 200-plus European fund managers, overseeing $482 billion in assets, found that 38% see European equities as undervalued. That&#8217;s the highest level in six years, according to the Financial Times.
"A plurality of investors expects Europe to be the best-performing equity market globally this year," BofA researchers noted, per Financial Times. A net 12% of respondents are now "overweight" European equities, compared to a net 25% who were "underweight" in December.
The rally in European equities is being powered by renewed economic optimism, potential fiscal stimulus in Germany, and a shift in sentiment among global investors. However, some experts urge caution. Pictet Asset Management's Luca Paolini warns that the rally is &#8220;based on hope, not facts,&#8221; with sentiment possibly overrunning fundamentals.
Whether the rally is sustainable remains to be seen, but for now, European stocks are back in focus.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43818555/trade-war-redux-a-bumpy-ride-ahead-for-these-etfs-after-trumps-tariff-move-on-auto-pharma-chip-imports">Trade War Redux: These ETFs Due For Bumpy Ride Thanks To Trump Tariffs On Auto, Pharma, Chip Imports</a></li>
</ul>
Photo: Shutterstock

Specialty ETFs

ETFs

DBEF

NOVO

Big Money Is Betting On Europe, Should You? 3 ETFs To Watch

<a href="https://www.benzinga.com/topic/george-soros">Billionaire investor George Soros</a> made some bold portfolio adjustments in the fourth quarter, signaling a shift toward growth while easing off defensive bets. 
Soros Fund Management's latest 13F filing shows fresh bets on Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) and small-cap stocks, alongside a significant reduction in its SPDR S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) put position.
Meanwhile, the fund trimmed its stake in Alibaba Group Holding Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABAF#NYSE">BABAF</a>) and fully exited Oracle Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>), reflecting a shifting stance on Chinese tech.
<h2 class="wp-block-heading">Doubling Down On Alphabet, Small Caps</h2>
Alphabet emerged as one of Soros' biggest buys, with the fund increasing its stake by 2.55%. 
The firm also ramped up its exposure to the iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>), a play on smaller, high-growth companies. 
This move suggests Soros is betting on a continued rebound in both mega-cap tech and smaller, more volatile stocks.
Read Also: <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43816112/hedge-fund-shake-up-tiger-appaloosa-soros-outperform-buffett-icahn-ackman">Hedge Fund Shake-Up: Tiger, Appaloosa, Soros Outperform Buffett, Icahn, Ackman</a>
<h2 class="wp-block-heading">Cutting Market Hedges, Adding Fixed Income</h2>
Soros Fund slashed its SPY put position by nearly 15%, signaling reduced bearish sentiment on the broader market. &#8216;
The fund also trimmed holdings in The Financial Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>) and iShares Core S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IVV#NYSE">IVV</a>), while increasing exposure to Ford Motor Co&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) debt and the iShares 20+ Year Treasury Bond ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLT#NASDAQ">TLT</a>) calls — moves that hint at an evolving fixed-income strategy.
<h2 class="wp-block-heading">China Exposure Shrinks As BABA Gets Trimmed</h2>
Alibaba stock took a hit in the fourth quarter as Soros scaled back his position, joining other investors in reassessing Chinese tech. 
Meanwhile, Smurfit WestRock PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SW#NYSE">SW</a>) remained the fund's top holding at 5.71% of the portfolio, with Alphabet and AstraZeneca PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) rounding out the top three.
Soros' latest moves suggest a more optimistic take on U.S. growth stocks while pulling back on market hedges and Chinese tech bets.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43811538/5-top-tech-stocks-hedge-funds-have-been-bullish-on-in-q4-hint-its-not-nvidia">5 Top Tech Stocks Hedge Funds Have Been Bullish On In Q4 (Hint: It&#8217;s Not Nvidia)</a></li>
</ul>
Image: Shutterstock

George Soros Makes Fresh Bets On Alphabet, Small Caps: What About SPY Puts And Alibaba?

<a href="https://www.ft.com/content/10795e9d-131a-47ba-9cce-b379f3abe8eb" title="https://www.ft.com/content/10795e9d-131a-47ba-9cce-b379f3abe8eb">https://www.ft.com/content/10795e9d-131a-47ba-9cce-b379f3abe8eb</a>

Legal

'AstraZeneca Hit With US Class Action Lawsuit Over China Regulatory Probes; Lawsuit Claims UK Pharma Giant Understated The Risk Of Government Investigations' - Financial Times

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>AZN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$77.50</td>
<td>$27.5K</td>
<td>206</td>
<td>6.0K</td>
</tr>
<tr>
<td>EYPT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$5.00</td>
<td>$49.7K</td>
<td>431</td>
<td>1.0K</td>
</tr>
<tr>
<td>TMDX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/19/25</td>
<td>$100.00</td>
<td>$37.1K</td>
<td>475</td>
<td>384</td>
</tr>
<tr>
<td>GILD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/07/25</td>
<td>$108.00</td>
<td>$38.3K</td>
<td>45</td>
<td>339</td>
</tr>
<tr>
<td>TEM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$60.00</td>
<td>$162.5K</td>
<td>3.5K</td>
<td>222</td>
</tr>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$60.00</td>
<td>$110.4K</td>
<td>5.0K</td>
<td>183</td>
</tr>
<tr>
<td>WST</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$240.00</td>
<td>$28.4K</td>
<td>5</td>
<td>136</td>
</tr>
<tr>
<td>WGS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$75.00</td>
<td>$257.3K</td>
<td>1.3K</td>
<td>134</td>
</tr>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$200.00</td>
<td>$106.5K</td>
<td>203</td>
<td>95</td>
</tr>
<tr>
<td>UNH</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$550.00</td>
<td>$171.4K</td>
<td>710</td>
<td>66</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• Regarding AZN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>), we observe a call option sweep with bearish sentiment. It expires in 213 day(s) on September 19, 2025. Parties traded 62 contract(s) at a $77.50 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $27.5K, with a price of $445.0 per contract. There were 206 open contracts at this strike prior to today, and today 6063 contract(s) were bought and sold. 
• For EYPT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYPT#NASDAQ">EYPT</a>), we notice a put option sweep that happens to be bearish, expiring in 332 day(s) on January 16, 2026. This event was a transfer of 500 contract(s) at a $5.00 strike. This particular put needed to be split into 18 different trades to become filled. The total cost received by the writing party (or parties) was $49.7K, with a price of $95.0 per contract. There were 431 open contracts at this strike prior to today, and today 1002 contract(s) were bought and sold. 
• For TMDX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>), we notice a call option sweep that happens to be bearish, expiring in 304 day(s) on December 19, 2025. This event was a transfer of 24 contract(s) at a $100.00 strike. This particular call needed to be split into 12 different trades to become filled. The total cost received by the writing party (or parties) was $37.1K, with a price of $1553.0 per contract. There were 475 open contracts at this strike prior to today, and today 384 contract(s) were bought and sold. 
• For GILD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>), we notice a call option sweep that happens to be bullish, expiring in 17 day(s) on March 7, 2025. This event was a transfer of 276 contract(s) at a $108.00 strike. This particular call needed to be split into 12 different trades to become filled. The total cost received by the writing party (or parties) was $38.3K, with a price of $139.0 per contract. There were 45 open contracts at this strike prior to today, and today 339 contract(s) were bought and sold. 
• For TEM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>), we notice a call option trade that happens to be bearish, expiring in 332 day(s) on January 16, 2026. This event was a transfer of 50 contract(s) at a $60.00 strike. The total cost received by the writing party (or parties) was $162.5K, with a price of $3250.0 per contract. There were 3527 open contracts at this strike prior to today, and today 222 contract(s) were bought and sold. 
• For CVS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), we notice a call option trade that happens to be bearish, expiring in 332 day(s) on January 16, 2026. This event was a transfer of 96 contract(s) at a $60.00 strike. The total cost received by the writing party (or parties) was $110.4K, with a price of $1150.0 per contract. There were 5079 open contracts at this strike prior to today, and today 183 contract(s) were bought and sold. 
• Regarding WST (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>), we observe a call option sweep with bearish sentiment. It expires in 213 day(s) on September 19, 2025. Parties traded 16 contract(s) at a $240.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $28.4K, with a price of $1780.0 per contract. There were 5 open contracts at this strike prior to today, and today 136 contract(s) were bought and sold. 
• Regarding WGS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGS#NASDAQ">WGS</a>), we observe a call option sweep with bullish sentiment. It expires in 3 day(s) on February 21, 2025. Parties traded 83 contract(s) at a $75.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $257.3K, with a price of $3100.0 per contract. There were 1316 open contracts at this strike prior to today, and today 134 contract(s) were bought and sold. 
• Regarding DHR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>), we observe a put option sweep with bearish sentiment. It expires in 213 day(s) on September 19, 2025. Parties traded 82 contract(s) at a $200.00 strike. This particular put needed to be split into 26 different trades to become filled. The total cost received by the writing party (or parties) was $106.5K, with a price of $1300.0 per contract. There were 203 open contracts at this strike prior to today, and today 95 contract(s) were bought and sold. 
• Regarding UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we observe a put option trade with bullish sentiment. It expires in 3 day(s) on February 21, 2025. Parties traded 40 contract(s) at a $550.00 strike. The total cost received by the writing party (or parties) was $171.4K, with a price of $4285.0 per contract. There were 710 open contracts at this strike prior to today, and today 66 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

EYPT

GILD

TMDX

10 Health Care Stocks Whale Activity In Today's Session

AstraZeneca's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NYSE">AZN</a>) short percent of float has risen 12.24% since its last report. The company recently reported that it has 16.94 million shares sold short, which is 0.55% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.64 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>AstraZeneca Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739802622_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for AstraZeneca has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing AstraZeneca's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, AstraZeneca's peer group average for short interest as a percentage of float is 4.08%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Is The Market Feeling About AstraZeneca?

Soros Fund Management Raises Share Stake In AstraZeneca By 19% To 3.2M Sponsored ADRs

Trump Order Halts Funding For School Covid Vaccine Mandates

On Friday, AstraZeneca Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) <a target="_blank" href="https://www.astrazeneca.com/media-centre/press-releases/2025/imfinzi-perioperative-regimen-improved-event-free-survival-and-overall-survival-of-niagara-phase-iii-trial.html" rel="noreferrer noopener">shared</a> results from a post-hoc exploratory subgroup analysis from the NIAGARA Phase 3 trial.
The study showed that Imfinzi&nbsp;(durvalumab), administered perioperatively in combination with neoadjuvant (before surgery) chemotherapy, demonstrated improvements in event-free survival (EFS) and overall survival (OS) versus neoadjuvant chemotherapy with radical cystectomy alone in patients with or without a pathologic complete response (pCR) in muscle-invasive bladder cancer (MIBC).
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43441313/astrazeneca-blames-toxic-climate-as-it-walks-away-from-over-550-million-uk-vaccine-plant" rel="noreferrer noopener">AstraZeneca Blames &#8216;Toxic&#8217; Climate As It Walks Away from Over $550 Million UK Vaccine Plant</a>
Patients were treated with four cycles of&nbsp;Imfinzi&nbsp;in combination with neoadjuvant chemotherapy before radical cystectomy (surgery to remove the bladder), followed by eight cycles of&nbsp;Imfinzi&nbsp;monotherapy.
In NIAGARA, treatment with the&nbsp;Imfinzi&nbsp;perioperative regimen improved EFS and OS versus the comparator arm in patients who achieved pCR and those who did not.
The regimen reduced the risk of disease progression, recurrence, not undergoing surgery, or death by 42% in patients who achieved pCR and by 23% in those who did not, and reduced the risk of death by 28% in patients who achieved pCR and by 16% in those who did not.
The&nbsp;Imfinzi&nbsp;perioperative regimen also improved metastasis-free survival (MFS) and disease-specific survival (DSS), two secondary endpoints, versus the comparator arm in the intent-to-treat (ITT) population.
This regimen reduced the risk of developing distant metastases or death by 33% and the risk of death specifically due to bladder cancer by 31% versus the comparator arm.
Imfinzi&nbsp;was generally well tolerated, and no new safety signals were observed in the neoadjuvant and adjuvant settings.
In December, the FDA accepted and granted Priority Review to a supplemental application seeking approval for&nbsp;<a target="_blank" href="https://www.benzinga.com/24/12/42363652/soon-after-approval-for-lung-cancer-astrazenecas-cancer-drug-imfinzi-goes-under-fda-priority-review-for-bladder-cancer" rel="noreferrer noopener">Imfinzi&nbsp;(durvalumab) for MIBC patients</a>.
The Prescription Drug User Fee Act date, the FDA action date for their regulatory decision, is anticipated during the second quarter of 2025.
Price Action: AZN stock is down 0.93% at $73.76 at the last check on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/25/02/43737860/coca-cola-pepsico-adjust-dei-policies-following-trump-executive-order-report" target="_blank" rel="noreferrer noopener">Coca-Cola, PepsiCo Adjust DEI Policies Following Trump Executive Order: Report</a></li>
</ul>
Image by Robert Way via Shutterstock

AstraZeneca's Imfinzi Perioperative Regimen Shows Improved Survival Outcomes In Bladder Cancer Patients

IMFINZI reduced the risk of distant metastases and death from bladder cancer vs. neoadjuvant chemotherapy alone
Results from a post-hoc exploratory subgroup analysis from the NIAGARA Phase III trial showed AstraZeneca's IMFINZI&#xAE;(durvalumab), administered perioperatively in combination with neoadjuvant chemotherapy, demonstrated improvements in event-free survival (EFS) and overall survival (OS) versus neoadjuvant chemotherapy with radical cystectomy alone in patients with or without a pathologic complete response (pCR) in muscle-invasive bladder cancer (MIBC). Patients were treated with four cycles of IMFINZI in combination with neoadjuvant chemotherapy before radical cystectomy (surgery to remove the bladder) followed by eight cycles of IMFINZI monotherapy.
These new data were presented today at the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) in San Francisco, California (abstract #659).
In NIAGARA, treatment with the IMFINZI perioperative regimen improved EFS and OS versus the comparator arm both in patients who achieved pCR and those who did not. This regimen reduced the risk of disease progression, recurrence, not undergoing surgery, or death by 42% in patients who achieved pCR and by 23% in those who did not; and reduced the risk of death by 28% in patients who achieved pCR and by 16% in those who did not (see data table below for details).
The IMFINZIperioperative regimen also improved metastasis-free survival (MFS) and disease-specific survival (DSS), two secondary endpoints, versus the comparator arm in the intent-to-treat (ITT) population. This regimen reduced the risk of developing distant metastases or death by 33% and the risk of death specifically due to bladder cancer by 31% versus the comparator arm (see data table below for details).

AstraZeneca's IMFINZI Perioperative Regimen Improved Event-Free Survival And Overall Survival Across Muscle-Invasive Bladder Cancer Patients Regardless Of Complete Pathology Response Status In Post-Hoc Exploratory Analysis Of Niagara Phase III Trial

On Wednesday, Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) reported a fourth-quarter EPS loss of 64 cents, beating the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus loss of 1.07 euros</a>.
Total revenue for the fourth quarter of 2024 was 173.9 million euros, beating the consensus of 111.178 million euros compared to 137.7 million <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43674382/ascendis-pharma-reports-fourth-quarter-and-full-year-2024-financial-results" rel="noreferrer noopener">euros reported a year ago</a>.
The increase was primarily due to Novo Nordisk A/S&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) $100 million upfront fee and the EU launch of Yorvipath.
TransCon hGH (lonapegsomatropin, marketed as Skytrofa) sales reached 58.5 million euros.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41723496/wegovy-manufacturer-inks-multi-million-deal-for-monthly-obesity-drug" rel="noreferrer noopener">Wegovy Manufacturer Inks Multi-Million Deal For Monthly Obesity Drug</a>
TransCon PTH (palopegteriparatide, marketed as Yorvipath) revenue for the fourth quarter of 2024 totaled €13.6 million.
The company reported a strong start to the U.S. Yorvipath launch, with 908 prescriptions as of February 7, 2025, and 539 unique prescribing health care providers.
As of December 31, 2024, cash and cash equivalents totaled 559.5 million euros. Including the $100 million upfront payment, cash at the end of 2024 would have totaled 655 million euros.
Concurrently, Ascendis Pharma's board authorized the repurchase of up <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43674574/ascendis-pharma-as-announces-share-repurchase-program-net-settlement-of-certain-rsus" rel="noreferrer noopener">to $18.25 million shares</a>.
Goldman Sachs analyst writes that Yorvipath has only been available in the U.S. for a few months, but early prescription trends have been strong and widespread. However, insurance coverage and reimbursement challenges may slow revenue growth in the short term.
Looking ahead, analyst Paul Choi writes investors will likely focus on the company's progress toward achieving breakeven cash flow and key milestones, including:
<ul>
<li>The pace of Yorvipath's rollout in the U.S. and EU</li>
<li>Data from the COACH study on achondroplasia, expected in Q2 2025</li>
<li>Regulatory discussions on Transcon CNP</li>
<li>Competitive updates from BioMarin Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) in achondroplasia and AstraZeneca Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) in hypoparathyroidism.</li>
</ul>
With Yorvipath showing potential for a strong launch in 2025, Goldman Sachs maintains the Buy rating and raises the price target <a target="_blank" href="https://www.benzinga.com/quote/CVS/analyst-ratings" rel="noreferrer noopener">to $225 from $200</a>.
Price Action: ASND stock is up 15.8% at $146.08 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/25/02/43697905/zoetis-drops-as-2025-guidance-falls-short-of-estimates" target="_blank" rel="noreferrer noopener">Zoetis Drops As 2025 Guidance Falls Short Of Estimates</a></li>
</ul>

Analyst Color

Earnings

Guidance

Price Target

Analyst Ratings

ASND

BMRN

Why Is Rare Disease Focused Ascendis Pharma Stock Trading Higher On Thursday?

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Leerink Partners analyst Michael Cherny upgraded the rating for CVS Health Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) from Market Perform to Outperform and raised the price target from $55 to $75. CVS Health shares closed at $63.22 on Wednesday. <a href="https://www.benzinga.com/quote/CVS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays analyst Duffy Fischer upgraded DuPont de Nemours, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DD#NYSE">DD</a>) from Underweight to Equal-Weight and boosted the price target from $85 to $89. DuPont shares closed at $81.76 on Wednesday. <a href="https://www.benzinga.com/quote/DD/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo analyst Mohit Bansal upgraded the rating for Jazz Pharmaceuticals plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) from Equal-Weight to Overweight and raised the price target from $130 to $170. Jazz Pharmaceuticals shares closed at $135.44 on Wednesday. <a href="https://www.benzinga.com/quote/JAZZ/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>UBS analyst Matthew Weston upgraded AstraZeneca PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) from Neutral to Buy. AstraZeneca shares closed at $74.43 on Wednesday. <a href="https://www.benzinga.com/quote/AZN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley analyst Jeffrey Hung upgraded the rating for Cytokinetics, Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) from Equal-Weight to Overweight but lowered the price target from $70 to $67. Cytokinetics shares closed at $42.18 on Wednesday. <a href="https://www.benzinga.com/quote/CYTL/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying AZN stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="574" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13073343/image-117-1024x574.png" alt="" class="wp-image-780826" style="width:608px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13073343/image-117-1024x574.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13073343/image-117-300x168.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13073343/image-117-768x431.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13073343/image-117.png 1088w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/02/43655479/top-3-utilities-stocks-that-may-collapse-in-q1">Top 3 Utilities Stocks That May Collapse In Q1</a></li>
</ul>

Upgrades

Pre-Market Outlook

CYTK

JAZZ

This AstraZeneca Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

UBS analyst Matthew Weston upgrades AstraZeneca (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) from Neutral to Buy.

UBS Upgrades AstraZeneca to Buy

On CNBC's &#8220;<a href="https://www.cnbc.com/video/2025/02/11/final-trades-trade-desk-leidos-holdings-astrazeneca-and-devon-energy.html">Halftime Report Final Trades</a>,&#8221; Joshua Brown of Ritholtz Wealth Management named The Trade Desk, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>) as <a href="https://www.benzinga.com/quote/TTD/earnings">his final trade</a>.
Trade Desk, meanwhile, will release its fourth-quarter financial results after the closing bell today. Analysts expect the Ventura, California-based company to report quarterly earnings at 57 cents per share, up from 41 cents per share in the year-ago period. Trade Desk projects quarterly revenue of $759.56 million, compared to $605.8 million a year earlier, according to data from Benzinga Pro.
Stephen Weiss of Short Hills Capital Partners said he is staying with Leidos Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LDOS#NYSE">LDOS</a>).
Supporting his view, on Tuesday Leidos Holdings reported fourth-quarter fiscal 2024 revenue growth of 10% year-over-year to $4.37 billion, beating the analyst consensus estimate of $4.13 billion. Demand across all customer segments, especially for managed health services, drove the increase.
Don't forget to check out our<a href="https://www.benzinga.com/premarket/"> premarket coverage here</a>
Jim Lebenthal of Cerity Partners said AstraZeneca PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) made a strong start to the year.
Adding support to his choice, AstraZeneca, on Feb. 6, reported fourth-quarter earnings and revenue above estimates. Sales of $14.89 billion, up 18% year over year (+19% at constant currency), topped the consensus of $14.29 billion.
Rounding out the trades, Jenny Van Leeuwen Harrington of Gilman Hill Asset Management, LLC said with oil above $70, Devon Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVN#NYSE">DVN</a>) is wildly profitable.
Supporting her view, Piper Sandler analyst Mark Lear, on Jan. 29, maintained Devon Energy with an Overweight rating and raised the price target from $53 to $54.
Price Action:
<ul>
<li>Trade Desk shares declined 1.9% to close at $120.21 on Tuesday.</li>
<li>Leidos shares fell 3.6% to settle at $137.60 during Tuesday's session.</li>
<li>AstraZeneca shares gained 0.1% to close at $72.73 on Tuesday.</li>
<li>Devon Energy shares gained 2.5% to settle at $35.12 during the session.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/02/43623929/wall-streets-most-accurate-analysts-spotlight-on-3-utilities-stocks-delivering-high-dividend-yields-6">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Utilities Stocks Delivering High-Dividend Yields</a></li>
</ul>
Photo: Shutterstock

Media

LDOS

Trade Desk, Leidos, Devon Energy And A Major Health Care Stock On CNBC's 'Final Trades'

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TEM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/14/25</td>
<td>$75.00</td>
<td>$39.4K</td>
<td>2.1K</td>
<td>8.1K</td>
</tr>
<tr>
<td>AHCO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$10.00</td>
<td>$71.4K</td>
<td>0</td>
<td>4.7K</td>
</tr>
<tr>
<td>THC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>02/21/25</td>
<td>$145.00</td>
<td>$105.8K</td>
<td>1.1K</td>
<td>1.0K</td>
</tr>
<tr>
<td>COR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$230.00</td>
<td>$822.5K</td>
<td>495</td>
<td>258</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$35.00</td>
<td>$81.1K</td>
<td>5.1K</td>
<td>217</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$270.00</td>
<td>$140.0K</td>
<td>355</td>
<td>200</td>
</tr>
<tr>
<td>SYK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$390.00</td>
<td>$39.6K</td>
<td>484</td>
<td>151</td>
</tr>
<tr>
<td>MCK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/28/25</td>
<td>$610.00</td>
<td>$53.0K</td>
<td>100</td>
<td>137</td>
</tr>
<tr>
<td>AZN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$67.50</td>
<td>$33.6K</td>
<td>1.8K</td>
<td>120</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$860.00</td>
<td>$25.3K</td>
<td>50</td>
<td>112</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• For TEM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>), we notice a call option trade that happens to be bearish, expiring in 3 day(s) on February 14, 2025. This event was a transfer of 200 contract(s) at a $75.00 strike. The total cost received by the writing party (or parties) was $39.4K, with a price of $197.0 per contract. There were 2192 open contracts at this strike prior to today, and today 8123 contract(s) were bought and sold. 
• Regarding AHCO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AHCO#NASDAQ">AHCO</a>), we observe a put option sweep with bearish sentiment. It expires in 220 day(s) on September 19, 2025. Parties traded 476 contract(s) at a $10.00 strike. This particular put needed to be split into 19 different trades to become filled. The total cost received by the writing party (or parties) was $71.4K, with a price of $150.0 per contract. There were 0 open contracts at this strike prior to today, and today 4752 contract(s) were bought and sold. 
• For THC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>), we notice a call option sweep that happens to be neutral, expiring in 10 day(s) on February 21, 2025. This event was a transfer of 300 contract(s) at a $145.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $105.8K, with a price of $355.0 per contract. There were 1108 open contracts at this strike prior to today, and today 1040 contract(s) were bought and sold. 
• Regarding COR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>), we observe a call option trade with bearish sentiment. It expires in 339 day(s) on January 16, 2026. Parties traded 250 contract(s) at a $230.00 strike. The total cost received by the writing party (or parties) was $822.5K, with a price of $3290.0 per contract. There were 495 open contracts at this strike prior to today, and today 258 contract(s) were bought and sold. 
• Regarding MRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), we observe a call option sweep with bullish sentiment. It expires in 339 day(s) on January 16, 2026. Parties traded 100 contract(s) at a $35.00 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $81.1K, with a price of $812.0 per contract. There were 5109 open contracts at this strike prior to today, and today 217 contract(s) were bought and sold. 
• For AMGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), we notice a put option trade that happens to be bullish, expiring in 129 day(s) on June 20, 2025. This event was a transfer of 200 contract(s) at a $270.00 strike. The total cost received by the writing party (or parties) was $140.0K, with a price of $700.0 per contract. There were 355 open contracts at this strike prior to today, and today 200 contract(s) were bought and sold. 
• For SYK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>), we notice a put option sweep that happens to be bearish, expiring in 10 day(s) on February 21, 2025. This event was a transfer of 99 contract(s) at a $390.00 strike. This particular put needed to be split into 23 different trades to become filled. The total cost received by the writing party (or parties) was $39.6K, with a price of $400.0 per contract. There were 484 open contracts at this strike prior to today, and today 151 contract(s) were bought and sold. 
• For MCK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>), we notice a call option sweep that happens to be bullish, expiring in 17 day(s) on February 28, 2025. This event was a transfer of 53 contract(s) at a $610.00 strike. This particular call needed to be split into 16 different trades to become filled. The total cost received by the writing party (or parties) was $53.0K, with a price of $1000.0 per contract. There were 100 open contracts at this strike prior to today, and today 137 contract(s) were bought and sold. 
• Regarding AZN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>), we observe a call option sweep with bearish sentiment. It expires in 65 day(s) on April 17, 2025. Parties traded 57 contract(s) at a $67.50 strike. This particular call needed to be split into 9 different trades to become filled. The total cost received by the writing party (or parties) was $33.6K, with a price of $590.0 per contract. There were 1841 open contracts at this strike prior to today, and today 120 contract(s) were bought and sold. 
• For LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we notice a put option trade that happens to be bearish, expiring in 157 day(s) on July 18, 2025. This event was a transfer of 4 contract(s) at a $860.00 strike. The total cost received by the writing party (or parties) was $25.3K, with a price of $6340.0 per contract. There were 50 open contracts at this strike prior to today, and today 112 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AHCO

10 Health Care Stocks With Whale Alerts In Today's Session

Investors with a lot of money to spend have taken a bullish stance on AstraZeneca (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>).
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with AZN, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 9 options trades for AstraZeneca.
This isn't normal.
The overall sentiment of these big-money traders is split between 55% bullish and 44%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $33,835, and 8, calls, for a total amount of $3,881,635.
<h3>Expected Price Movements</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $65.0 and $77.5 for AstraZeneca, spanning the last three months.
<h3>Analyzing Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of AstraZeneca stands at 1003.75, with a total volume reaching 7,809.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in AstraZeneca, situated within the strike price corridor from $65.0 to $77.5, throughout the last 30 days.
<h3>AstraZeneca Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739215824_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>AZN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$5.9</td>
<td>$5.55</td>
<td>$5.8</td>
<td>$77.50</td>
<td>$1.9M</td>
<td>3.1K</td>
<td>0</td>
</tr>
<tr>
<td>AZN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$3.3</td>
<td>$3.15</td>
<td>$3.2</td>
<td>$75.00</td>
<td>$1.0M</td>
<td>2.4K</td>
<td>3.5K</td>
</tr>
<tr>
<td>AZN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$2.34</td>
<td>$2.0</td>
<td>$2.3</td>
<td>$77.50</td>
<td>$689.9K</td>
<td>535</td>
<td>3.0K</td>
</tr>
<tr>
<td>AZN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$8.2</td>
<td>$8.15</td>
<td>$8.15</td>
<td>$65.00</td>
<td>$39.1K</td>
<td>920</td>
<td>368</td>
</tr>
<tr>
<td>AZN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$8.0</td>
<td>$7.8</td>
<td>$8.0</td>
<td>$65.00</td>
<td>$38.3K</td>
<td>920</td>
<td>740</td>
</tr>
</tbody>
</table>

<h3>About AstraZeneca</h3>
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its sales.
Having examined the options trading patterns of AstraZeneca, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Where Is AstraZeneca Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 4,149,033, with AZN's price up by 0.87%, positioned at $72.61.</li>
<li>RSI indicators show the stock to be may be overbought.</li>
<li>Earnings announcement expected in 73 days.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for AstraZeneca, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Unpacking the Latest Options Trading Trends in AstraZeneca

Financial giants have made a conspicuous bullish move on AstraZeneca. Our analysis of options history for AstraZeneca (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) revealed 11 unusual trades.
Delving into the details, we found 63% of traders were bullish, while 18% showed bearish tendencies. Out of all the trades we spotted, 6 were puts, with a value of $320,360, and 5 were calls, valued at $216,678.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $60.0 to $95.0 for AstraZeneca over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
In today's trading context, the average open interest for options of AstraZeneca stands at 1822.71, with a total volume reaching 912.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in AstraZeneca, situated within the strike price corridor from $60.0 to $95.0, throughout the last 30 days.
<h3>AstraZeneca Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738854938_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>AZN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$21.55</td>
<td>$21.2</td>
<td>$21.55</td>
<td>$95.00</td>
<td>$161.6K</td>
<td>1</td>
<td align="right">75</td>
</tr>
<tr>
<td>AZN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$20.85</td>
<td>$19.15</td>
<td>$19.34</td>
<td>$60.00</td>
<td>$56.0K</td>
<td>117</td>
<td align="right">50</td>
</tr>
<tr>
<td>AZN</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>04/17/25</td>
<td>$7.2</td>
<td>$6.85</td>
<td>$7.0</td>
<td>$67.50</td>
<td>$51.8K</td>
<td>1.8K</td>
<td align="right">96</td>
</tr>
<tr>
<td>AZN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$4.75</td>
<td>$4.7</td>
<td>$4.75</td>
<td>$70.00</td>
<td>$42.7K</td>
<td>2.8K</td>
<td align="right">12</td>
</tr>
<tr>
<td>AZN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$21.7</td>
<td>$21.65</td>
<td>$21.7</td>
<td>$95.00</td>
<td>$41.2K</td>
<td>1</td>
<td align="right">75</td>
</tr>
</tbody>
</table>

<h3>About AstraZeneca</h3>
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its sales.
<h3>Present Market Standing of AstraZeneca</h3>
<ul>
<li>Trading volume stands at 1,628,717, with AZN's price up by 4.08%, positioned at $73.83.</li>
<li>RSI indicators show the stock to be may be overbought.</li>
<li>Earnings announcement expected in 0 days.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for AstraZeneca, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

AstraZeneca Unusual Options Activity

Press Releases

AZN Deadline: Rosen Law Firm Encourages AstraZeneca PLC Investors to Secure Counsel Before Important February 21 Deadline in Securities Class Action First Filed by the Firm – AZN

AstraZeneca PLC Class Action: The Gross Law Firm Reminds AstraZeneca Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 21, 2025 - AZN

Faruqi & Faruqi Reminds AstraZeneca Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 21, 2025 - AZN

DEADLINE ALERT for CPRI, AZN, RIG: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of February 21, 2025 in AstraZeneca PLC Lawsuit – AZN

Final Deadline for the AstraZeneca PLC Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - AZN

AZN Deadline: AZN Investors Have Opportunity to Lead AstraZeneca PLC Securities Fraud Lawsuit Filed by The Rosen Law Firm

Lost Money on AstraZeneca PLC(AZN)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AstraZeneca

AstraZeneca PLC Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before February 21, 2025 to Discuss Your Rights – AZN

CPRI

Axsome Therapeutics

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Takeda Pharmaceutical Co

Teva Pharmaceutical Industries Limited American Depositary Shares

Teva Pharmaceutical Indus

Verona Pharma plc - American Depositary Shares

Verona Pharma

Viatris

Zoetis

TD Cowen

Argus Research

Goldman Sachs

BMO Capital

Morgan Stanley

Screenshot 2024-09-30 at 9.13.36 PM

TNXP

VRTX

The Rush For Non-Addictive Painkillers To Counter The Opioid Crisis Puts Two Companies Closer To FDA Decisions

Screenshot 2024-09-30 at 5.38.54 PM

Movers & Shakers

COSM

Nestle Sponsored representing Registered Shares Series B

NSRGY

VTRS

How Cosmos Health&#39;s Acquisition Of Almost 100-Year-Old Company, Adding To Capabilities Like Contract Manufacturing, Could Generate Over $10 Million In Annual Gross Profit

Screenshot 2024-03-13 at 5.45.52 PM

FDXTF

SHTDY

Nanotechnology&#39;s Promising Role In Fighting Infectious Diseases: Protecting Surfaces With FendX&#39;s Nanotechnology

Screenshot 2023-07-10 at 5.56.06 PM

GNPX

Gene Therapy Company Genprex, Inc. (NASDAQ: GNPX) Receives Fast Track Designation From The FDA For Its Small Cell Lung Cancer Drug Candidate

<a href="https://www.benzinga.com/topic/george-soros">억만장자 투자자 조지 소로스</a>는 4분기에 대담한 포트폴리오 조정을 단행하여 방어적 베팅을 완화하고 성장 쪽으로 방향을 전환했다.
소로스 펀드 매니지먼트의 최신 13F 제출서는 알파벳(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>)과 소형주들에 대한 새로운 베팅을 보여주었으며, SPDR S&amp;P 500 ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) 풋 포지션을 대폭 줄였다.
한편, 이 펀드는 알리바바 그룹 홀딩(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABAF#NYSE">BABAF</a>)에 대한 지분을 축소하고 오라클(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>)에 대해서는 완전히 매도하여 중국 기술주에 대한 입장을 변화시켰다.
<h2 class="wp-block-heading">알파벳과 소형주에 대한 투자 확대</h2>
알파벳은 소로스의 주요 매수 종목 중 하나로, 이 펀드는 지분을 2.55% 늘렸다.
또한 iShares Russell 2000 ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>)에 대한 노출을 확대하여 소형 고성장 기업들에 대한 투자를 강화했다.
이러한 움직임은 소로스가 대형 기술주와 소형주, 변동성이 큰 주식의 지속적인 반등을 예상하고 있음을 시사다.
또한 읽어보세요: <a href="https://kr.benzinga.com/news/usa/stocks/%ED%97%A4%EC%A7%80%ED%8E%80%EB%93%9C-%EC%A7%80%EA%B0%81-%EB%B3%80%EB%8F%99-%ED%83%80%EC%9D%B4%EA%B1%B0-%EC%95%84%ED%8C%94%EB%A3%A8%EC%82%AC-%EC%86%8C%EB%A1%9C%EC%8A%A4%EA%B0%80-%EB%B2%84%ED%95%8F/" target="_blank" rel="noopener">헤지펀드 지각 변동: 타이거, 아팔루사, 소로스가 버핏, 아이칸, 애크먼을 능가</a>
<h2 class="wp-block-heading">시장 헤지 축소, 고정 수익 추가</h2>
소로스 펀드는 SPY 풋 포지션을 거의 15% 줄여 전반적인 시장에 대한 비관적 전망을 완화했다.
이 펀드는 The Financial Select Sector SPDR Fund(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>)와 iShares Core S&amp;P 500 ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IVV#NYSE">IVV</a>)에 대한 보유량도 축소하고, 포드 자동차(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>)의 채권과 iShares 20+ Year Treasury Bond ETF(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLT#NASDAQ">TLT</a>) 콜 옵션에 대한 노출을 증가시켜 채권 전략의 변화를 암시했다.
<h2 class="wp-block-heading">중국 노출 축소 및 BABA 지분 축소</h2>
알리바바 주식은 소로스가 포지션을 축소하면서 4분기에 타격을 입었으며, 이는 다른 투자자들이 중국 기술주를 재평가하는 데 동참한 것이다.
한편, 스머핏 웨스트록 PLC(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SW#NYSE">SW</a>)는 포트폴리오의 5.71%로 펀드의 주요 보유 종목을 유지했으며, 알파벳과 아스트라제네카 PLC(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>)가 상위 3위에 올랐다.
소로스의 최신 움직임은 미국 성장주에 대한 보다 낙관적인 시각을 제시하는 동시에 시장 헤지와 중국 기술주 베팅을 축소하고 있음을 시사한다.
다음 읽기: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43811538/5-top-tech-stocks-hedge-funds-have-been-bullish-on-in-q4-hint-its-not-nvidia"><a href="https://kr.benzinga.com/news/usa/stocks/4%EB%B6%84%EA%B8%B0%EC%97%90-%ED%97%A4%EC%A7%80%ED%8E%80%EB%93%9C%EA%B0%80-%EA%B8%8D%EC%A0%95%EC%A0%81%EC%9C%BC%EB%A1%9C-%ED%8F%89%EA%B0%80%ED%95%9C-%EC%83%81%EC%9C%84-5%EA%B0%9C-%EA%B8%B0%EC%88%A0/" target="_blank" rel="noopener">4분기 헤지펀드가 긍정적으로 평가한 5대 기술 주식 (힌트: 엔비디아가 아님)</a></a></li>
</ul>
이미지 출처: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

아킬레스 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHL#NASDAQ">ACHL</a>)의 주식은 회사가 아스트라제네카(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>)와 1,200만 달러 규모의 계약을 발표하고, <a href="https://www.benzinga.com/pressreleases/24/12/g42669546/achilles-therapeutics-announces-sale-of-technology-assets-to-astrazeneca" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">일자리 감축 계획</a>을 밝힌 후 화요일 16% 이상 급등했다.
이번 계약은 아킬레스의 TRACERx 비소세포폐암(NSCLC) 연구로부터 데이터와 종양 샘플에 대한 상업적 라이선스 이전을 아스트라제네카에 허용하는 내용을 포함하고 있다.
이 백만 달러 규모의 거래는 아킬레스의 전략적 검토 결정을 마무리짓는 신호로, 이는 2024년 9월에 발표된 바 있다.
거래 완료 후 아킬레스는 직원 수를 줄이고 이사회의 규모를 축소할 계획을 밝혔으며, 이는 나스닥 및 미 증권거래위원회(SEC) 요구사항을 준수하는 범위 내에서 진행된다.
<div class="ticker-wrapper">
<div class="sc-icgYrN gsJcQM ticker-box-wrapper">
<div class="sc-hZlppA ddOBfh get-report-button flex">
<div> </div>
</div>
</div>
</div>
&#8220;아킬레스는 이제 추가 조치를 취할 계획이며, 여기에는 직원 수의 추가 감소와 이사회의 규모 축소가 포함된다. 이는 나스닥 및 SEC 요구사항을 준수하는 범위 내에서 이루어질 것이다&#8221;고 이 회사가 언급했다.
추가 읽기: <a href="https://www.benzinga.com/news/large-cap/24/12/42668623/american-airlines-resolves-nationwide-flight-grounding-on-christmas-eve-shares-rebound-after-brief-selloff">아메리칸 항공, 크리스마스 이브 비행 중단 해제, 주가 반등</a>
TRACERx 연구는 런던 대학교(UCL)의 찰스 스완튼(Charles Swanton) 교수의 주도로 진행되었으며, 800명 이상의 폐암 환자로부터 3,200개 이상의 종양 샘플에서 광범위한 유전적 데이터를 수집했다.
이 다지역, 다시간점 시퀀싱 연구는 암의 진화와 치료 반응에 대한 깊은 통찰력을 제공한다.
계약의 일환으로 아스트라제네카는 또한 아킬레스의 물질 획득 플랫폼(MAP)을 인수하게 되며, 이 플랫폼은 폐암, 흑색종, 유방암 등 다양한 고형 종양 적응증에서 수집된 거의 300명의 암 환자 종양 샘플과 데이터를 포함하고 있다.
&#8220;종양학 분야의 선두주자인 아스트라제네카가 우리의 TRACERx와 MAP 자산의 과학적 가치를 인정해 주셔서 기쁘다&#8221;라고 이라지 알리 박사(Dr. Iraj Ali), 아킬레스 테라퓨틱스의 CEO가 말했다.
이 회사는 이러한 자산들이 개선된 암 치료제 개발에 상당한 잠재력을 가지고 있다고 믿고 있다.
가격 동향: ACHL 주식은 화요일16.17% 승승한 $1.14로 마감했다. 이후 시간외 거래에서 1.75% 추가 상승했다.
 
다음 읽기:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42660092/microstrategy-sinks-after-nasdaq-100-inclusion-bitcoin-bet-under-fire" target="_blank" rel="noreferrer noopener">마이크로스트레티지, 나스닥 100 포함 후 하락: 비트코인 베팅 논란?</a></li>
</ul>
사진 출처: Johaehn from Pixabay


Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

지난주 카멀라 해리스가 2024년 미국 대선에서 패배하면서 다음 10개의 대형 주식이 가장 저조한 성과를 보였다.
1. 모더나(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>)는 3분기 실적이 예상치를 상회했음에도 불구하고 백신 수요 감소로 인한 부진으로 12.53% 하락했다. 여러 <a href="https://www.benzinga.com//node/41854205" target="_blank" rel="noreferrer noopener">애널리스트들이 목표주가를 하향 조정</a>했다.
2. 혼다 모터 컴퍼니(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HMC#NYSE">HMC</a>)는 상반기 이익 감소와 연간 수익 전망 하향 조정으로 11.46% 하락했다.
3. 아카마이 테크놀로지스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKAM#NASDAQ">AKAM</a>)는 <a href="https://www.benzinga.com//node/41823455" target="_blank" rel="noreferrer noopener">2024회계연도 가이던스를 수정</a>한 후 주가가 10.67% 하락했다.
4. 어드밴스트 드레이니지 시스템즈(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMS#NYSE">WMS</a>)는 2분기 실적이 예상보다 저조하게 나타나고 2025회계연도 <a href="https://www.benzinga.com//node/41839671" target="_blank" rel="noreferrer noopener">순매출 전망을 하향 조정</a>한 후 10.53% 하락했다.
5. 아스트라제네카(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>)는 회사의 보험 사기에 <a href="https://www.benzinga.com//node/41754167" target="_blank" rel="noreferrer noopener">중국 고위 임원 관련 연루 소식</a>이 보도된 후 9.72% 하락했다.
6. 핀터레스트(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PINS#NYSE">PINS</a>)는 3분기 실적을 발표하고 여러 애널리스트들이 <a href="https://www.benzinga.com//node/41850902" target="_blank" rel="noreferrer noopener">목표주가를 하향 조정</a>한 후 9.60% 하락했다.
7. 메르카도리브레(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MELI#NASDAQ">MELI</a>)는 3분기 재무 실적을 발표한 후 9.29% 하락했다.
8. 퍼스트 솔라(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>)는 아마도 도널드 트럼프의 대선 승리 소식 때문인지 8.64% 하락했다. 투자자들이 트럼프의 <a href="https://www.benzinga.com//node/41778433" target="_blank" rel="noreferrer noopener">태양광 및 재생 에너지 정책</a>을 평가하고 있을 수 있다.
9. 포스코 홀딩스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PKX#NYSE">PKX</a>)는 8.42% 하락했다.
10. 플로어 앤 데코 홀딩스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FND#NYSE">FND</a>)는 8.22% 하락했다.
더 읽기:
<ul>
<li><a style="font-size: revert; font-weight: revert;" href="https://kr.benzinga.com/news/usa/stocks/%EB%8F%84%EB%84%90%EB%93%9C-%ED%8A%B8%EB%9F%BC%ED%94%84-%EC%8A%B9%EB%A6%AC-%EC%A3%BC11%EC%9B%94-4%EC%9D%BC-8%EC%9D%BC-%EC%9D%B4%EB%93%A4-10%EA%B0%9C-%EB%8C%80%ED%98%95%EC%A3%BC%EB%8A%94-%EA%B0%80/" target="_blank" rel="noopener">도널드 트럼프 승리 주(11월 4일-8일): 이들 10개 대형주는 가장 큰 폭의 상승 기</a><a href="https://www.benzinga.com/news/large-cap/24/11/41886058/donald-trump-victory-week-nov-4-8-these-large-cap-stocks-were-biggest-gainers" target="_blank" rel="noreferrer noopener">록</a> 
</li>
</ul>
이미지 출처: Shutterstock
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스 기사를 이용하면 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

아스트라제네카(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>)는 2024년 3분기 실적을 <a href="https://www.benzinga.com/quote/AZN/earnings">화요일 아침</a>에 발표할 예정이며, 이 회사의 2분기 실적은 종양학 및 심혈관 포트폴리오에 의해 촉진된 강력한 성장을 암시한다.
알아야 할 사항: 2분기 동안 아스트라제네카는 <a href="https://www.benzinga.com/general/biotech/24/07/39958623/astrazeneca-posts-mixed-q2-earnings-still-raises-annual-guidance-on-strong-demand-for-cancer-rare">129.4억 달러의 매출</a>를 기록하여 전년 대비 13% 증가(상수 통화 기준 17%)를 나타내었으며, 애널리스트들이 예상한 127.5억 달러를 초과했다.
이는 주요 치료 영역 전반에 걸친 꾸준한 수요와 고효능 의약품의 인상적인 배열에 의해 뒷받침되었다. ADR(일반주식 2주에 해당)당 조정된 주당순이익(EPS)은 99센트로 컨센서스와 일치하였고, 조정된 EPS는 1.98달러에 달했다.
아스트라제네카의 종양학 부문은 여전히 가장 큰 매출 동력으로, 매출이 15% 증가하여 53.3억 달러에 달했다. 주요 기여 약물로는 암 치료제 타그리소(Tagrisso), 임핀지(Imfinzi) 및 칼퀀스(Calquence)로 각각 16억 1천만 달러, 11억 5천만 달러 그리고 7억 9천만 달러를 창출했다.
타그리소의 인기는 전 세계적으로 계속 상승하고 있으며, 이는 매출이 8% 증가한 것(상수 통화 기준 12%)으로 반영되었다. 1차 만성 림프구성 백혈병(CLL)에 대한 주요 치료제인 칼퀀스는 매출이 21% 증가했다.
엔허투(Enhertu)는 다이이찌산쿄(Daiichi Sankyo)와의 협업으로 개발된 것으로, 시장에서의 긍정적인 반응을 보여주며 46%의 놀라운 성장을 기록했다.
추가 사항: 심혈관, 신장 및 대사(CVRM) 부문도 2분기 동안 유사한 성과를 보였으며, 매출이 18% 증가하여 31.6억 달러에 달했다. 아스트라제네카의 주요 당뇨병 및 심부전 치료제인 파시가(Farxiga)는 19.5억 달러를 기여하며 매출이 29% 증가했다.
호흡기 및 면역학(R&amp;I) 역시 브레즈트리(Breztri) 매출이 44% 증가하고 천식 치료제 테즈스파이어(Tezspire) 매출이 거의 두 배 증가하는 등 상당한 이익을 얻었다. 희귀질환 치료제도 긍정적으로 기여했으며, 울토미리스(Ultomiris)가 이 부문의 10% 성장을 주도하여 기존 약물인 솔리리스(Soliris)의 감소를 상쇄했다.
아스트라제네카는 전체 회계연도 동안 매출과 핵심 EPS 모두 중간 10대 성장률을 예상하고 있으며, 이는 기존 치료제와 새로운 적응증으로의 확장에 의해 주도된다. 이 회사가 COVID-19 백신 매출에서 벗어나면서 종양학 및 CVRM 중심의 강력한 포트폴리오로 전환하고 있다.
주가 움직임: <a href="https://benzinga.grsm.io/register174" target="_blank" rel="noopener">벤징가 프로</a>의 데이터에 따르면, 아스트라제네카의 주식은 월요일 0.47% 상승한 64.79달러에 마감되었다. 이후 시간외 거래에서 0.^0% 추가 상승했다. AZN의 52주 최고가는 87.67달러, 최저가는 60.48달러이다.
다음 읽기: 
• <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41878981/microstrategy-acquires-another-27200-bitcoin-worth-2-billion">마이크로스트레티지, 비트코인 27,200개 추가 매입: 20억 달러 가치</a>
사진: Shutterstock
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Previews

아스트라제네카 3분기 실적 미리보기: 암과 심장 치료약이 계속된 성장을 견인할까?

화요일 존슨앤드존슨(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>)은 선불금 6억 달러로 V-웨이브(V-Wave)를 인수하기로 합의했으며, 추가 규제 및 상업적 마일스톤 지불 가능성은 최대 <a href="https://www.benzinga.com/pressreleases/24/08/b40458486/johnson-johnson-to-acquire-v-wave" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">약 11억 달러</a>에 이른다.
V-웨이브는 심부전 및 심혈관 질환 치료 옵션 개발에 주력하는 비상장 의료기기 회사이다.
V-웨이브는 존슨앤드존슨 메드텍(MedTech)의 일부로 존슨앤드존슨에 합류하게 된다.
이 계획된 V-웨이브 인수로 심혈관 질환 해결 분야에서 존슨앤드존슨 메드텍의 입지가 확대될 것이다.
고성장·고기회 시장으로의 전환을 더욱 가속화할 것이다.
V-웨이브의 벤츄라 심방간 션트(Ventura Interatrial Shunt(IAS))는 좌심방과 우심방 사이에 션트를 생성하여 울혈성 심부전 시 상승된 좌심방 압력을 감소시키도록 설계된 이식형 장치이다. 이는 심혈관 사건과 심부전 입원을 감소시킨다.
이번 거래는 2024년 말 전에 마무리할 예정이다.
존슨앤드존슨은 이번 거래로 인해 조정 주당순이익(EPS)가 2024년에는 약 0.24달러, 2025년에는 약 0.06달러 희석될 것으로 예상하고 있다.
화요일에 미 식품의약국(FDA)은 존슨앤드존슨의 라이브레반트(amivantamab)와 라즈클루즈(lazertinib)를 상피세포 성장인자 수용체(EGFR) 엑손 19 결손 또는 엑손 21 L858R <a href="https://www.benzinga.com/pressreleases/24/08/n40457728/rybrevant-amivantamab-vmjw-plus-lazcluze-lazertinib-approved-in-the-u-s-as-a-first-line-chemothera" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">치환 돌연변이</a>를 가진 국소 진행성 또는 전이성 비소세포 폐암(NSCLC) 성인 환자의 1차 치료제로 승인했다.
이 중요한 성과로, 라이브레반트(Rybrevant)와 라즈클루즈(Lazcluze) 조합은 EGFR 변이 비소세포 폐암(NSCLC) 환자의 1차 치료제로 승인된 다중 표적, 화학요법이 없는 조합 요법 중에서 아스트라제네카(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>)의 타그리소(osimertinib)와 비교하여 우수성이 입증된 최초이자 유일한 치료제가 되었다.
이번 FDA 승인은 오시머티닙(osimertinib)에 비해 질병 진행 또는 사망 위험을 30% 감소시킨 3상 MARIPOSA 연구 결과를 바탕으로 이루어졌다(중앙값 무진행 생존기간 23.7개월 대 16.6개월).
연구의 2차 평가변수인 라이브레반트 + 라즈클루즈 대 오시머티닙(25.8개월 대 16.7개월)의 경우 평균 반응 기간이 9개월 더 길었다.
가격 움직: 화요일 존슨앤드존슨의 주식은 0.33% 상승한 160.16달러에 마감되었다.
사진: 셔터스톡
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

존슨앤드존슨은 심부전 혁신업체 V-웨이브를 인수하기 위해 17억 달러 거래 체결

목요일 아침 (현지 시간 기준) 미국 주식 선물이 더 높게 거래되면서 오늘 투자자의 관심을 끌 수 있는 일부 주식은 다음과 같다:
<ul>
<li>월스트리트는 허니웰 인터내셔널(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HON#NASDAQ">HON</a>)가 개장 전에 94억 1천만 달러의 매출과 94억 1천만 달러의 분기 이익을 주당 2.42달러로 보고할 것으로 예상하고 있다. <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>의 데이터에 따르면 허니웰의 주식은 시간외 거래에서 0.5% 상승한 214.80달러를 기록했다.</li>
<li>아스트라제네카(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>)는 2분기에 예상보다 나은 실적을 기록했으며 2024년 매출 및 이익 지침을 높였다.아스트라제네카의 주가는 시간외 거래에서 0.3% 하락한 79.46달러를 기록했다.</li>
<li>분석가들은 노스롭 그루먼(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOC#NYSE">NOC</a>)이 매출 100억 2천만 달러, 주당 5.93달러의 분기 이익을 기록할 것으로 예상하고 있다. 이 회사는 시장이 열리기 전에 실적을 발표할 예정이다. 노스롭 그루먼의 주가는 시간외 거래에서 0.2% 상승한 443.00달러를 기록했다.</li>
</ul>
저희 <a href="https://www.benzinga.com/premarket/">프리마켓 동향 커버리지를 확인하세요.</a>
<ul>
<li>사노피(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>)는 2분기에 긍정적인 실적을 발표하고 2024년 실적 전망을 상향 조정했다. 사노피의 주가는 시간외 거래에서 0.1% 하락한 51.13달러를 기록했다.</li>
<li>분석가들은 아메리칸 항공 그룹(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAL#NASDAQ">AAL</a>)이 개장 전에 143억 6천만 달러의 매출과 주당 1.05달러의 분기 이익을 발표할 것으로 예상한다. 아메리칸 항공 주가는 수요일 3% 하락한 10.17달러로 마감했다.</li>
</ul>
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

목요일 주목해야 할 주식: 아메리칸 항공, 아스트라제네카 그리고 3종목

S&amp;P 500 기업들 중 약 <a href="https://www.benzinga.com/news/earnings/24/07/39769910/goldman-sachs-q2-earnings-revenue-and-eps-beat-investment-banking-fees-up-21-hikes-dividend" target="_blank" rel="noopener" data-google-interstitial="false">14%가 6월 분기 실적을 발표</a>했으며, 더 넓은 지수를 구성하는 기업들의 혼합 실적 성장률은 여전히 ​​양호하다. 이번 주에는 기술 보고 시즌이 공식적으로 시작될 것이며, 이는 최근 주에 가파른 하락세를 보인 시장의 향방을 잠재적으로 결정할 수 있다.
지난주 주요 사건: 기술주의 실적 시즌은 지난주 칩 장비 제조업체 ASML 홀딩 N.V.(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>)의 실적 발표로 와만하게 시작되었다. 이 회사의 주가는 약한 3분기 전망과 중국 칩 금지를 둘러싼 지정학적 우려로 인해 약 16% 하락했다. 넷플릭스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>)의 지침은 투자자들을 실망시켰지만 증권사 측 분석가들이 결과에 열광하면서 주가는 크게 하락하지 않았다.
투자자들은 뱅크 오브 아메리카(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>), 모건 스탠리(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MS#NYSE">MS</a>) 및 골드만삭스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) 등 나머지 대형 은행들의 실적 보고서에 환호했다. 투자 은행 사업의 반등과 강력한 트레이딩 매출이 은행들의 매출을 강화하는 데 도움이 되었다.
팩트셋(FactSet)의 최신 실적 전망 조사 <a href="https://advantage.factset.com/hubfs/Website/Resources%20Section/Research%20Desk/Earnings%20Insight/EarningsInsight_071924.pdf">보고서</a>에 따르면 이들 기업 중 80%가 예상보다 높은 주당 이익을 보고했는데, 이는 5년 평균인 77%와 비교된다. 평균 상승 여력은 약 5.5%이지만, 이는 5년 평균 상승률 8.6%보다 낮다.
관련 정보: <a href="https://www.benzinga.com/money/best-tech-stocks">지금 가장 핫한 기술주</a>
실적 트렌드: 팩트셋에 따르면 S&amp;P 500 기업들의 2분기 혼합 실적 증가율은 현재 9.7%로 전주의 9.1%보다 높아진 것으로 추정된다. 이 추정치가 달성되면 분기 실제 성장률은 2021년 4분기 이후 보고된 전년 동기 대비 가장 높은 성장률을 기록할 것이라고 덧붙였다. 2분기 역시 4분기 연속 성장을 기록할 것으로 보인다.
S&amp;P 500 11개 부문 중 8개 부문이 전년 동기 대비 실적 성장을 기록할 것으로 예상되며, 그 중 통신 서비스, 의료, IT, 금융 부문 4개 부문이 두 자릿수 실적 성장을 기록할 가능성이 높다. 반면, 소재 업종을 중심으로 3개 업종의 실적 감소가 예상된다.
이번 주의 이슈: 이번 주에는 다우 30 지수 구성요소 7개를 포함해 S&amp;P 500 기업 138개 기업들의 실적 보고서가 나올 것이라고 팩트셋의 보고서가 밝혔다. 이번 주의 실적 발표 목록에는 통신, 자동차, 철강, 칩, 주택 건설, 방위, 항공 및 기술 산업의 기업들이 포함된다.
테슬라(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)와 알파벳(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>)은 S&amp;P 500과 나스닥 지수에서 높은 비중을 차지하고 있어 주목받는 기업들 중 하나이다. 테슬라는 전년 동기 대비 주당 순이익이 91센트에서 62센트로 급격히 감소할 것으로 예상되는 반면, 매출은 훨씬 완만하게 0.80% 감소한 247억 3천만 달러를 기록했을 수 있다. 이 이익성에 더 큰 영향을 미치는 것은 일론 머스크의 회사가 어려운 수요 환경에서 생산량을 늘리기 위해 의존해 온 가격 인하에서 비롯된다.
<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39810457/as-tesla-stock-bounces-back-fund-manager-says-elon-musk-led-company-offers-good-set">분석가들과 펀드 매니저들은</a> 회사가 해당 분기에 양호한 납품 실적을 보고한 후 낙관적이다. 하반기에도 반전이 있을 것으로 예상된다.
알파벳의 실적은 AI를 활용한 거대 기업들 중 최초로 분기별 실적을 발표하는 기업이기 때문에 중요하며, 이는 나머지 기업들의 실적 속도를 정할 수 있다.
지난주 주요 지수가 사상 최고치에서 후퇴하면서 주식시장이 큰 타격을 입었다. Benzinga Pro 데이터에 따르면 나스닥 100 지수의 성과를 추적하는 지수인 Invesco QQQ Trust(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)는 금요일 0.89% 하락한 475.24달러에 마감했다. 이 ETF는 7월 10일에 도달한 502.96달러의 사상 최고치보다 낮게 거래되고 있다. SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)도 금요일 0.66% 하락한 548.99달러로 마감했다.
이번 주 주목할 만한 실적 발표 기업은 다음과 같다:
월요일
개장 전:
<ul>
<li>버라이즌 커뮤니케이션스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NYSE">VZ</a>)</li>
</ul>
장 마감 후:
<ul>
<li>애질리시스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGYS#NASDAQ">AGYS</a>)</li>
<li>클리블랜드 클리프스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLF#NYSE">CLF</a>)</li>
<li>뉴코 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUE#NYSE">NUE</a>)</li>
<li>NXP 반도체 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPI#NASDAQ">NXPI</a>)</li>
</ul>
화요일
개장 전:
<ul>
<li>코카콜라 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>)</li>
<li>프리포트 맥모란 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCX#NYSE">FCX</a>)</li>
<li>GATX 코퍼레이션 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GATX#NYSE">GATX</a>)</li>
<li>GE 에어로스페이스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GE#NYSE">GE</a>)</li>
<li>제너럴 모터스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>)</li>
<li>킴벌리 클라크 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMB#NYSE">KMB</a>)</li>
<li>록히드 마틴 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>)</li>
<li>필립 모리스 인터내셔널 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PM#NYSE">PM</a>)</li>
<li>풀트그룹 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHM#NYSE">PHM</a>)</li>
<li>퀘스트 다이아그노스틱스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>)</li>
<li>스포티파이 테크놀로지 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>)</li>
<li>UPS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>)</li>
</ul>
장 마감 후:
<ul>
<li>알파벳</li>
<li>캐피털 원 파이낸셜 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COF#NYSE">COF</a>)</li>
<li>처브 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CB#NYSE">CB</a>)</li>
<li>마텔 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAT#NASDAQ">MAT</a>)</li>
<li>패키징 코퍼레이션 오브 아메리카 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PKG#NYSE">PKG</a>)</li>
<li>씨게이트 테크놀로지 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STX#NASDAQ">STX</a>)</li>
<li>테슬라</li>
<li>텍사스 인스트루먼트 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>)</li>
<li>비자 .(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>)</li>
</ul>
수요일
개장 전:
<ul>
<li>AT&amp;T (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/T#NYSE">T</a>)</li>
<li>체크포인트 소프트웨어 테크놀로지스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHKP#NASDAQ">CHKP</a>)</li>
<li>보스톤 사이언티픽 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>)</li>
<li>CME 그룹 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CME#NASDAQ">CME</a>)</li>
<li>제너럴 다이내믹스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GD#NYSE">GD</a>)</li>
<li>올드 도미니언 프레이트 라인 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODFL#NASDAQ">ODFL</a>)</li>
<li>GE 베르노바 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>)</li>
<li>써모 피셔 사이언티픽 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>)</li>
</ul>
장 마감 후:
<ul>
<li>치폴레 멕시칸 그릴 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>)</li>
<li>에드워드 라이프사이언스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>)</li>
<li>포드 자동차 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>)</li>
<li>IBM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>)</li>
<li>나이트 스위프트 트랜스포테이션 홀딩스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNX#NYSE">KNX</a>)</li>
<li>라스베가스 샌즈 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LVS#NYSE">LVS</a>)</li>
<li>메리티지 홈즈 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTH#NYSE">MTH</a>)</li>
<li>월풀 코퍼레이션 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WHR#NYSE">WHR</a>)</li>
<li>서비스나우 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>) ORLY</li>
<li>오릴리 오토모티브 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORLY#NASDAQ">ORLY</a>)</li>
</ul>
목요일
개장 전:
<ul>
<li>애브비 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>)</li>
<li>아메리칸 항공 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAL#NASDAQ">AAL</a>)</li>
<li>아스트라제네카 PLC(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>)</li>
<li>컴캐스트 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCSA#NASDAQ">CMCSA</a>)</li>
<li>다우 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOW#NYSE">DOW</a>)</li>
<li>해즈브로 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HAS#NASDAQ">HAS</a>)</li>
<li>허니웰 인터내셔널 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HON#NASDAQ">HON</a>)</li>
<li>사노피 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>)</li>
<li>사우스웨스트 항공 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUV#NYSE">LUV</a>)</li>
<li>ST마이크로일렉트로닉스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STM#NYSE">STM</a>)</li>
<li>유니언 퍼시픽 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNP#NYSE">UNP</a>)</li>
<li>제록스 홀딩스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRX#NASDAQ">XRX</a>)</li>
</ul>
장 마감 후:
<ul>
<li>스카이웨스트 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKYW#NASDAQ">SKYW</a>)</li>
<li>주니퍼 네트웍스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNPR#NYSE">JNPR</a>)</li>
<li>데커스 아웃도어 코퍼레이션 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DECK#NYSE">DECK</a>)</li>
<li>보이드 게이밍 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BYD#NYSE">BYD</a>)</li>
<li>BJ 레스토랑 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJRI#NASDAQ">BJRI</a>)</li>
<li>베리사인 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRSN#NASDAQ">VRSN</a>)</li>
</ul>
금요일
개장 전:
<ul>
<li>3M 컴퍼니(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMM#NYSE">MMM</a>)</li>
<li>반즈 그룹 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/B#NYSE">B</a>)</li>
<li>브리스톨-마이어스 스퀴브 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)</li>
<li>뉴웰 브랜즈 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWL#NASDAQ">NWL</a>)</li>
<li>콜게이트 파몰리브 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>)</li>
<li>차터 커뮤니케이션즈 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>)</li>
</ul>
차기 기사:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/07/39857569/american-express-q2-earnings-ceo-raises-annual-profit-and-marketing-spend-outlook-after-q2-profit-b">아메리칸 익스프레스, 2분기 실적: CEO의 2분기 순이익 안정화에 대한 전망</a></li>
</ul>
Photo: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

AstraZeneca

뉴스

에 대한 최신 뉴스 AstraZeneca (NASDAQ:AZN) 주식

수요일, 2월 19, 2025

수요일, 12월 25, 2024

월요일, 11월 11, 2024

화요일, 8월 20, 2024

목요일, 7월 25, 2024

일요일, 7월 21, 2024

일요일, 4월 07, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌